Atilotrelvir for COVID-19: real-time analysis

Download Image

Post

c19early.org

Atilotrelvir for COVID-19

1 study with >1,000 patients

Significantly lower risk for recovery and viral clearance.

COVID-19 Atilotrelvir studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)13%

Viral clearance (1)25%

RCTs (1)13%

Early (1)13%

00.511.5+

← Atilotrelvir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Atilotrelvir was adopted in 1 country.


May 31 2024	Lu et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102582	Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
May 31 2024	13% faster recovery (p=0.03) and 25% faster viral clearance (p<0.0001). RCT 1,213 outpatients with mild-to-moderate COVID-19 in China showing a shorter time to sustained recovery and faster viral clearance with GST-HG171 (atilotrelvir) plus ritonavir.